Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Rhea-AI Summary

Adverum Biotechnologies (NASDAQ:ADVM) announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Laurent Fischer, MD, President and CEO, along with Szilárd Kiss, MD, Distinguished Professor of Ophthalmology and Board Member, will engage in a fireside chat on August 13, 2025, at 9:00 AM EDT.

The presentation will be accessible via live webcast through Adverum's website investor section, with a replay available for at least 30 days after the event.

News Market Reaction – ADVM

-2.78%

1 alert

-2.78% News Effect

-$1M Valuation Impact

$51M Market Cap

1.2x Rel. Volume

On the day this news was published, ADVM declined 2.78%, reflecting a moderate negative market reaction. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $51M at that time.

Data tracked by StockTitan Argus on the day of publication.

REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5^th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 at 9:00am EDT.

A live webcast of the fireside chat can be accessed in the Investors section of Adverum’s website at www.adverum.com. An archived replay of the webcast will be available for at least 30 days following the presentation.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

Corporate and Investor Inquiries:

Adverum Investor Relations
Email: ir@adverum.com

Media:
Jason Awe, Ph.D.
Executive Director, Corporate Communications
Email: jawe@adverum.com

FAQ

When is Adverum Biotechnologies (ADVM) presenting at the H.C. Wainwright Ophthalmology Conference?

Adverum will present on Wednesday, August 13, 2025 at 9:00 AM EDT in a fireside chat format.

Who will represent Adverum Biotechnologies at the H.C. Wainwright Conference?

Laurent Fischer, MD (President and CEO) and Szilárd Kiss, MD (Distinguished Professor of Ophthalmology and Board Member) will represent Adverum.

How can investors access Adverum's presentation at the H.C. Wainwright Conference?

Investors can access the presentation via live webcast in the Investors section of Adverum's website at www.adverum.com.

How long will the replay of Adverum's H.C. Wainwright Conference presentation be available?

An archived replay of the webcast will be available for at least 30 days following the presentation.